Thoughts on Kaiser Acquiring Geisinger
A former colleague came across an article I wrote last year, 'My Recent Experience with Kaiser Health System' [...]
A former colleague came across an article I wrote last year, 'My Recent Experience with Kaiser Health System' [...]
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, [...]
As with many things in life, change is challenging, often undetected when it starts, many times mislabeled [...]
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin [...]
Health insurers are required to hold minimum levels of surplus each year. However, the exact amount a [...]
For a healthcare system to run efficiently there is a balance that needs to be found where there [...]
In the world of employee benefits, organizations and brokers often find themselves struggling to get a clear [...]
Introduction There is a coming wave of changes arriving soon to the pharmacy market in the form of [...]
Introduction About 30 years ago I met with my then-business partner to think into the future and [...]
Introduction Today is the day! The Big Event of 2023 is the launch of multiple Humira biosimilars [...]